Fusion Antibodies (LON:FAB) Trading Up 14.3% – Time to Buy?

Shares of Fusion Antibodies plc (LON:FAB) were up 14.3% during mid-day trading on Tuesday . The company traded as high as GBX 8.40 ($0.11) and last traded at GBX 8.40 ($0.11). Approximately 1,025,288 shares were traded during mid-day trading, a decline of 38% from the average daily volume of 1,646,707 shares. The stock had previously closed at GBX 7.35 ($0.09).

Fusion Antibodies Price Performance

The business’s 50-day simple moving average is GBX 8.02 and its 200-day simple moving average is GBX 5.37. The stock has a market cap of £7.90 million, a PE ratio of -1.89 and a beta of 0.49. The company has a quick ratio of 2.36, a current ratio of 3.87 and a debt-to-equity ratio of 2.40.

Fusion Antibodies (LON:FAB) last announced its earnings results on Tuesday, November 19th. The company reported GBX (0.80) (($0.01)) earnings per share for the quarter. Fusion Antibodies had a negative net margin of 195.95% and a negative return on equity of 137.11%. On average, research analysts expect that Fusion Antibodies plc will post -129.9999875 EPS for the current fiscal year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation.